This precision medicine oncology company develops targeted cancer therapies through integrated small-molecule drug discovery, structural biology, and biomarker identification, with a clinical pipeline of nine candidates focused on genetic disease drivers in solid tumors. The company's lead program is darovasertib, an oral PKC inhibitor for uveal melanoma patients with GNAQ/11 mutations, complemented by a portfolio of antibody-drug conjugates and targeted combination therapies addressing synthetic lethality pathways and molecularly defined tumor populations including MTAP-deleted and DLL3-expressing cancers. Revenue is generated through regulatory approvals and commercialization of approved products, supported by strategic partnerships including a major agreement with Servier for darovasertib rights outside the U.S., with manufacturing outsourced to contract partners and commercialization planned through a specialty sales force.